𝛼SK or Search

ENTITY

Biocytogen Pharmaceuticals (2315 HK)

74

Analysis

Industrials • China

Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs and preclinical research services. It offers gene-editing services, preclinical pharmacology and efficacy evaluation, and sells animal models under its BioMice™ sub-brand. The company also utilizes its proprietary RenMice® platforms for fully human antibody discovery. It was founded in 2008 and is headquartered in Beijing, China.

more

Refresh

Exchange Announcement • 17 Sep 2026 19:28

2026 Interim Report

Exchange Announcement • 16 Sep 2026 18:22

Poll Results Of The 2026 Third Extraordinary General Meeting Held On September 16, 2026

Exchange Announcement • 27 Aug 2026 16:38

Form Of Proxy For The Use At The 2026 Third Extraordinary General Meeting Held On Wednesday, September 16, 2026

Exchange Announcement • 27 Aug 2026 16:36

Notice Of The 2026 Third Extraordinary General Meeting

Exchange Announcement • 27 Aug 2026 16:33

Change In Implementation Method Of Certain Proceeds-Funded Project; And Notice Of The 2026 Third Extraordinary General Meeting

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x